Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$112.05 USD
+5.73 (5.39%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $112.09 +0.04 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Brokerage Reports
Jazz Pharmaceuticals PLC [JAZZ]
Reports for Purchase
Showing records 121 - 140 ( 249 total )
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
4Q18 Results; Blowout Quarter and Solid Guidance Provide Relief; But No Long Term Visibility
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
3Q18 Results; Taking Stock of and Reiterating our Neutral Thesis; M-A and Xyrem Life Cycle Remain Wildcards
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
Company: Jazz Pharmaceuticals PLC
Industry: Medical - Drugs
2Q18 Results; Vyxeos Challenge a Reminder That M-A Is No Free Lunch; Reiterate Neutral but Raise to $167
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O